DEVELOPMENT OF GASTRORETENTIVE MUCOADHESIVE SOLID DOSAGES FORM CONTAINING AMOXICILLIN TRIHYDRATE AND RANITIDINE HCL FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTIONS
H. pylori infection treatment approaches
Mucoadhesion can be explored in the design of drug delivery system. Mucoadhesive drug delivery systems interact with the mucus layer covering the mucosal epithelial surface, and mucin molecules, thus increasing the residence time of the dosage form at the site of absorption. The drugs having local action or possessing maximum absorption in gastrointestinal tract (GIT) requires increased duration of stay in GIT. Gastroretentive Mucoadhesive solid dosages form containing Amoxicillin Trihydrate and Ranitidine HCL were formulated to prolong the residence time of the dosage form at the site of application or absorption, and it results in intimate contact of the dosage form with the underline absorption surface. This combination is approved by FDA for the treatment of Helicobacter Pylori Infections. The formulation results in efficient absorption, enhanced bioavailability of the drugs due to a high surface to volume ratio and an improved therapeutic performance of the drug. The prolonged release of drug resulted in reduced frequency of drug administration and improved patient compliance. The optimized formulation was evaluated for various parameters i.e. hardness, friability, thickness, weight variation, drug content, dissolution study and swelling index.